PET Imaging with Amyvid for Alzheimer's
Video: Roberto Soto, MD, discusses using PET imaging with Amyvid for Alzheimer’s evaluation, including reimbursement, training, and benefits of the new test.
The FDA in April approved the radioactive diagnostic agent florbetapir, name brand Amyvid, for use with PET imaging for the evaluation of Alzheimer’s disease.
As the first FDA-approved agent for brain imaging of amyloid plaques in patients with cognitive impairment who are being evaluated for Alzheimer’s and other causes, Amyvid binds to amyloid plaques, considered a key player in Alzheimer’s disease, and is detected in PET scans.
A scan showing few or no amyloid plaques would mean a reduced likelihood the impairment is due to Alzheimer’s and can help rule out the disease. A positive scan showing moderate to frequent amyloid plaques is present in people with Alzheimer’s, as well as patient with other neurologic conditions and normal aging.
Last year, the FDA expressed concerns about radiologists’ ability to consistently read the scans, so Amyvid developer Ely Lilly developed a reader training program.
As the number of sites using Amyvid continues to grow, Diagnostic Imaging visited Precision Imaging in Rockville, Md., which has been using the agent for a few years as part of clinical trials.
In this video, Roberto Soto, MD, founder and medical officer of Precision Imaging, discusses the reimbursement challenges, the training provided, and the utility of the new imaging test.
What is the Best Use of AI in CT Lung Cancer Screening?
April 18th 2025In comparison to radiologist assessment, the use of AI to pre-screen patients with low-dose CT lung cancer screening provided a 12 percent reduction in mean interpretation time with a slight increase in specificity and a slight decrease in the recall rate, according to new research.
The Reading Room: Racial and Ethnic Minorities, Cancer Screenings, and COVID-19
November 3rd 2020In this podcast episode, Dr. Shalom Kalnicki, from Montefiore and Albert Einstein College of Medicine, discusses the disparities minority patients face with cancer screenings and what can be done to increase access during the pandemic.
Can CT-Based AI Radiomics Enhance Prediction of Recurrence-Free Survival for Non-Metastatic ccRCC?
April 14th 2025In comparison to a model based on clinicopathological risk factors, a CT radiomics-based machine learning model offered greater than a 10 percent higher AUC for predicting five-year recurrence-free survival in patients with non-metastatic clear cell renal cell carcinoma (ccRCC).
Could Lymph Node Distribution Patterns on CT Improve Staging for Colon Cancer?
April 11th 2025For patients with microsatellite instability-high colon cancer, distribution-based clinical lymph node staging (dCN) with computed tomography (CT) offered nearly double the accuracy rate of clinical lymph node staging in a recent study.
